Individualized Tuberculosis Therapy

What is individualized tuberculosis therapy?

Individualized tuberculosis (TB) therapy is a modern treatment approach in which the drug regimen for tuberculosis is specifically tailored to the unique characteristics of each patient. Unlike standardized treatment protocols, this approach systematically accounts for the resistance profile of the pathogen, the overall health status of the patient, potential drug interactions, and individual risk factors.

Tuberculosis is caused by the bacterium Mycobacterium tuberculosis and remains one of the leading infectious causes of death worldwide. The need for individualized therapy has grown significantly due to the increasing spread of resistant TB strains, including multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB).

Reasons for individualized therapy

Several factors may necessitate deviation from standard TB treatment protocols:

• Drug resistance: Resistance to first-line drugs such as isoniazid or rifampicin requires alternative drug combinations.
• Comorbidities: Conditions such as HIV/AIDS, diabetes mellitus, renal insufficiency, or liver disease affect the choice and dosing of medications.
• Intolerances and adverse effects: Some patients cannot tolerate certain standard medications, requiring the use of alternative agents.
• Patient-specific factors: Age, body weight, pregnancy, and genetic variations in drug metabolism all play an important role.
• Previous treatment history: Patients with prior TB therapy have an increased risk of resistance development.

Diagnostics as the foundation of individualization

Precise diagnostics are essential for individualized treatment planning. Key diagnostic measures include:

• Culture and drug susceptibility testing (DST): The pathogen is cultured from patient samples and tested for susceptibility to various antibiotics.
• Molecular rapid tests: Methods such as the Xpert MTB/RIF assay and line probe assays (LPA) enable rapid identification of resistance, particularly to rifampicin and isoniazid.
• Whole-genome sequencing (WGS): Comprehensive genomic analysis of the pathogen provides a full resistance profile and supports treatment decisions in complex cases.
• Therapeutic drug monitoring (TDM): Measurement of drug levels in the blood allows for individualized dose adjustments to optimize both efficacy and tolerability.

Treatment strategies

Treatment of drug-susceptible tuberculosis

In patients with drug-susceptible TB that responds to standard medications, the classic short-course chemotherapy is used. This involves an intensive phase of two months with isoniazid, rifampicin, pyrazinamide, and ethambutol, followed by a continuation phase of four months with isoniazid and rifampicin. Even in these cases, individual adjustments may be necessary, for example in patients with liver disease or renal insufficiency.

Treatment of multidrug-resistant tuberculosis (MDR-TB)

MDR-TB, defined as resistance to at least isoniazid and rifampicin, requires individually composed treatment regimens. Recent WHO recommendations favor shorter, all-oral regimens such as the BPaL regimen (bedaquiline, pretomanid, linezolid) or the BPaLM regimen (additionally moxifloxacin). The selection of drugs is based on the individual resistance profile and the clinical condition of the patient.

Treatment in the presence of comorbidities

In HIV-positive patients, interactions between antiretroviral drugs and TB medications, particularly rifampicin, must be carefully managed. In patients with renal insufficiency, dose adjustments are required for several agents. Pregnant patients require special consideration regarding the teratogenic potential of individual drugs.

The role of therapeutic drug monitoring

Therapeutic drug monitoring (TDM) is a key tool in individualized TB therapy. By regularly measuring drug concentrations in blood plasma, dosages can be adjusted to achieve therapeutically effective levels without exceeding toxic thresholds. This is especially important in patients with altered drug absorption, metabolic disorders, or when reserve medications with a narrow therapeutic window are used.

Treatment duration and therapeutic success

Treatment duration varies considerably depending on the form of tuberculosis and the individual response to therapy. While drug-susceptible TB can typically be treated within six months, MDR-TB or XDR-TB therapy may last 18 to 24 months or longer. Newer, individualized regimens such as BPaLM aim to shorten treatment duration to six months even for MDR-TB. Regular microbiological monitoring documents treatment progress.

Challenges and future perspectives

Individualized TB therapy places high demands on diagnostic infrastructure, clinical expertise, and interdisciplinary collaboration. In resource-limited settings, which are disproportionately affected by TB, access to molecular diagnostics and reserve medications is often restricted. Future developments include the increased use of artificial intelligence for treatment optimization, new drug combinations, and improved point-of-care diagnostics to bring individualized treatment within reach in low-income regions.

References

1. World Health Organization (WHO): WHO consolidated guidelines on tuberculosis. Module 4: Treatment. Geneva: WHO, 2022. Available at: https://www.who.int/publications/i/item/9789240048126
2. Lange C, Chesov D, Heyckendorf J et al.: Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment. Respirology. 2018;23(7):656-673. doi:10.1111/resp.13304
3. Tiberi S, du Plessis N, Walzl G et al.: Tuberculosis: Progress and advances in development of new drugs, treatment regimens, and host-directed therapies. The Lancet Infectious Diseases. 2018;18(7):e183-e198. doi:10.1016/S1473-3099(18)30110-5